|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Neurology Antibody, CBA IFA
Test Code93890
Includes
Antibodies to NMDAR1, AMPAR1, AMPAR2, GABABR, LGI1, CASPR2
Preferred Specimen
Red Top
Minimum Volume
0.3 mL
Other Acceptable Specimens
CSF collected in a sterile screw-cap container
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Serum Separator Tube (SST®)
Methodology
Cell Binding Assay-Immunofluorescence Assay (CBA-IFA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 2 days a week.
Reference Range
| NMDAR1 Ab, CBA | Negative |
| AMPAR1 Ab, CBA | Negative |
| AMPAR2 Ab, CBA | Negative |
| GABABR Ab, CBA | Negative |
| LGI1 Ab, CBA | Negative |
| CASPR2 Ab, CBA | Negative |
Clinical Significance
Autoantibodies to brain neurotransmitter cell surface receptors may be seen in paraneoplastic syndromes or in idiopathic autoimmune encephalitis. Antibodies to N-methyl-D-aspartate receptor (NMDAR1) may be seen in a progressive syndrome leading to behavioral changes, psychosis, seizures and coma; teratoma or other neoplasms are seen in some cases. Antibodies to voltage gated potassium channel (VGKC) are found in paraneoplastic and idiopathic autoimmune encephalopathy; in many cases, antibodies actually target VGKC-associated proteins LGI-1 or CASPR2. Antibodies to AMPAR1 and AMPAR2 are usually associated with limbic encephalitis but can present with other symptoms or psychosis, and is paraneoplastic in >50% of cases.
